November 25, 2016 - By Marie Mckinney · 0 Comments
The stock of Bioanalytical Systems Incorporated (NASDAQ:BASI) registered a decrease of 14% in short interest. BASI’s total short interest was 30,100 shares in November as published by FINRA. Its down 14% from 35,000 shares, reported previously. With 4,500 shares average volume, it will take short sellers 7 days to cover their BASI’s short positions. The short interest to Bioanalytical Systems Incorporated’s float is 0.46%. About 88 shares traded hands. Bioanalytical Systems, Inc. (NASDAQ:BASI) has declined 38.83% since April 22, 2016 and is downtrending. It has underperformed by 44.24% the S&P500.
Bioanalytical Systems, Inc. is a contract research organization (CRO) providing drug discovery and development services and analytical instruments. The company has a market cap of $4.81 million. The Firm operates through two divisions: contract research services and research products. It currently has negative earnings. The Company’s contract research services segment provides research and development support on a contract basis directly to pharmaceutical companies.
Insitutional Activity: The institutional sentiment increased to 4 in Q2 2016. Its up 3.29, from 0.71 in 2016Q1. The ratio increased, as 3 funds sold all Bioanalytical Systems, Inc. shares owned while 4 reduced positions. 2 funds bought stakes while 3 increased positions. They now own 232,433 shares or 1.45% less from 235,863 shares in 2016Q1.
Dimensional Fund Advsr Limited Partnership has 0% invested in the company for 53,411 shares. The California-based Blackrock Fund Advisors has invested 0% in Bioanalytical Systems, Inc. (NASDAQ:BASI). Citadel Advisors Llc accumulated 0% or 12,739 shares. Acadian Asset Limited Liability Company owns 1,110 shares or 0% of their US portfolio. Jpmorgan Chase Com has 100 shares for 0% of their US portfolio. Goldman Sachs Gp has 23,374 shares for 0% of their US portfolio. North Star Asset Management Incorporated has 0% invested in the company for 20,000 shares. Barclays Public Ltd owns 83 shares or 0% of their US portfolio. Tower Rech Limited Com (Trc) has 42 shares for 0% of their US portfolio. State Street accumulated 10,200 shares or 0% of the stock. Ladenburg Thalmann Fin last reported 3 shares in the company. Vanguard Grp Inc owns 92,596 shares or 0% of their US portfolio. Renaissance Tech Limited Liability Corp has 0% invested in the company for 17,700 shares.
Bioanalytical Systems, Inc., incorporated on July 17, 1975, is an international contract research organization providing drug discovery and development services and analytical instruments. The Company’s clients and partners include pharmaceutical, biotechnology, academic and government organizations. The Firm derives its revenues from sales of its research services and drug development tools. The Firm supports the preclinical and clinical development needs of researchers and clinicians for small molecule and biomolecule drug candidates. The Company’s principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the global pharmaceutical companies. The Firm operates in two business divisions: contract research services and research products, both of which addresses the bioanalytical, preclinical, and clinical research needs of drug developers.
More recent Bioanalytical Systems, Inc. (NASDAQ:BASI) news were published by: Marketwatch.com which released: “Bioanalytical Systems Inc.” on December 21, 2009. Also Seekingalpha.com published the news titled: “Bioanalytical Systems’ (BASI) CEO Jacqueline Lemke on Q3 2016 Results …” on August 12, 2016. Streetinsider.com‘s news article titled: “Bioanalytical Systems (BASI) Adds Alba Therapeutics CEO as Director” with publication date: December 14, 2015 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marie Mckinney